{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:52:36Z","timestamp":1791985956067,"version":"4.4.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"\n Importance<\/jats:title>\n The optimal vasopressor dose at which to initiate a second vasopressor in patients with septic shock is uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the effects of hospital-level strategies initiating vasopressin infusion at a lower threshold vs a higher threshold on outcomes in patients with septic shock.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Cluster-randomized, cluster-crossover, pragmatic clinical strategy trial including adult patients receiving vasopressors for septic shock at 13 hospitals in Idaho and Utah from February 1, 2024, to July 31, 2025. The last day of follow-up for the primary outcome was February 17, 2026.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Hospital-level implementation of septic shock management strategies recommending fixed-dose vasopressin initiation when the total dose of other vasopressors reached 0.1 \u00b5g\/kg\/min of norepinephrine or equivalent (lower-threshold strategy) or when the total dose of other vasopressors reached 0.4 \u00b5g\/kg\/min of norepinephrine or equivalent (higher-threshold strategy). Hospitals were randomized for the first month to an initial strategy (6 hospitals to the lower threshold vs 7 hospitals to the higher threshold) and then crossed over to the alternate strategy monthly thereafter.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome of 28-day mortality and the key secondary outcome of kidney replacement therapy\u2013free days through day 28 were analyzed using multivariable generalized linear mixed-effects models, accounting for trial site and baseline patient characteristics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n There were 3959 unique patients with septic shock (median age, 68 [IQR, 57 to 77] years; 1903 [48%] were female). Of the patients more likely to experience differential management under the tested hospital-level vasopressin dose strategies (maximum vasopressor dose \u22650.07 \u00b5g\/kg\/min of norepinephrine or equivalent), 1034 of 1521 (68.0%) cared for under the lower-threshold strategy received vasopressin compared with 651 of 1526 (42.7%) cared for under the higher-threshold strategy. In the hospital-level strategy recommending a lower-dose threshold for vasopressin initiation, the maximum vasopressor dose received prior to vasopressin initiation was a median of 0.14 (IQR, 0.10 to 0.22) \u00b5g\/kg\/min of norepinephrine or equivalent vs 0.34 (IQR, 0.16 to 0.42) \u00b5g\/kg\/min of norepinephrine or equivalent in the hospital-level strategy recommending a higher-dose threshold for vasopressin initiation. Mortality at 28 days occurred in 628 of 1975 patients (31.8%) treated with the hospital-level strategy recommending initiation of vasopressin at a lower-dose threshold of other vasopressors vs 655 of 1984 patients (33.0%) treated with the higher-threshold strategy (adjusted marginal odds ratio, 0.98 [95% CI, 0.87 to 1.06],\n P<\/jats:italic>\n \u2009=\u2009.62; adjusted risk difference, \u22120.4 [95% CI, \u22122.7 to 1.3] percentage points). Patients in both strategies for vasopressin initiation had a median of 29 (IQR, \u22121 to 29) kidney replacement therapy\u2013free days (adjusted marginal odds ratio, 1.01 [95% CI, 0.91 to 1.14]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this large, pragmatic clinical trial comparing the effectiveness of 2 hospital-level strategies for second-line vasopressor management in septic shock, a strategy recommending initiation of vasopressin at a lower dose of other vasopressors did not reduce 28-day mortality compared with a strategy recommending vasopressin initiation at a higher dose of other vasopressors.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06217562<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.21333","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:30:22Z","timestamp":1791984622000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of Vasopressin Initiation Threshold on Septic Shock Mortality"],"prefix":"10.1001","author":[{"given":"Ithan D.","family":"Peltan","sequence":"first","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Groat","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth H.","family":"Tillman","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Klippel","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Brintz","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chauv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Arizmendez","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Beesley","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliotte L.","family":"Hirshberg","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"},{"name":"Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, Department of Medicine, School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lanspa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Intermountain Medical Center, Murray, Utah"},{"name":"Digital Technology Services, Intermountain Health, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Hu","sequence":"additional","affiliation":[{"name":"Digital Technology Services, Intermountain Health, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara D.","family":"Moores Todd","sequence":"additional","affiliation":[{"name":"Digital Technology Services, Intermountain Health, Salt Lake City, Utah"},{"name":"Department of Emergency Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Bledsoe","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin T.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Park City Hospital, Park City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Semler","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Casey","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin K.","family":"Grissom","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"},{"name":"Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, Department of Medicine, School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"},{"name":"Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, Department of Medicine, School of Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Leither","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"10219","key":"joi260122r1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study.","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"joi260122r2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.2014.2637","article-title":"Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.","volume":"311","author":"Kaukonen","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"joi260122r3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1164\/rccm.202309-1636OC","article-title":"Temporal trends in mortality of critically ill patients with sepsis in the United Kingdom, 1988-2019.","volume":"209","author":"Prescott","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"joi260122r4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1378\/chest.12-1106","article-title":"Survival after shock requiring high-dose vasopressor therapy.","volume":"143","author":"Brown","year":"2013","journal-title":"Chest"},{"issue":"6","key":"joi260122r5","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s00134-019-05620-2","article-title":"Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.","volume":"45","author":"Nagendran","year":"2019","journal-title":"Intensive Care Med"},{"issue":"5","key":"joi260122r6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","article-title":"Vasopressin deficiency contributes to the vasodilation of septic shock.","volume":"95","author":"Landry","year":"1997","journal-title":"Circulation"},{"issue":"3","key":"joi260122r7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1378\/chest.120.3.989","article-title":"Physiology of vasopressin relevant to management of septic shock.","volume":"120","author":"Holmes","year":"2001","journal-title":"Chest"},{"issue":"18","key":"joi260122r8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2018.4528","article-title":"Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis.","volume":"319","author":"McIntyre","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"joi260122r9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1164\/rccm.202002-0339OC","article-title":"Norepinephrine dysregulates the immune response and compromises host defense during sepsis.","volume":"202","author":"Stolk","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"joi260122r10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1164\/rccm.201604-0862CP","article-title":"Potentially inadvertent immunomodulation: norepinephrine use in sepsis.","volume":"194","author":"Stolk","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"joi260122r11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1097\/01.CCM.0000266683.64081.02","article-title":"Mechanisms of sepsis-induced cardiac dysfunction.","volume":"35","author":"Rudiger","year":"2007","journal-title":"Crit Care Med"},{"issue":"1","key":"joi260122r12","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1097\/CCM.0000000000003471","article-title":"Renal outcomes of vasopressin and its analogs in distributive shock: a systematic review and meta-analysis of randomized trials.","volume":"47","author":"Nedel","year":"2019","journal-title":"Crit Care Med"},{"issue":"1","key":"joi260122r13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13054-025-05540-2","article-title":"Vasopressin and its analogues in patients with septic shock: holy grail or unfulfilled promise?","volume":"29","author":"Lajoye","year":"2025","journal-title":"Crit Care"},{"issue":"11","key":"joi260122r14","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021.","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"issue":"4","key":"joi260122r15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/CCM.0000000000007089","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026.","volume":"54","author":"Prescott","year":"2026","journal-title":"Crit Care Med"},{"issue":"5","key":"joi260122r16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00134-025-08204-5","article-title":"Mastering the practical application of vasopressin at the bedside in septic shock.","volume":"52","author":"Leone","year":"2026","journal-title":"Intensive Care Med"},{"issue":"9","key":"joi260122r17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock.","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"joi260122r18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1001\/jama.2025.3046","article-title":"Optimal vasopressin initiation in septic shock: the OVISS Reinforcement Learning Study.","volume":"333","author":"Kalimouttou","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"joi260122r19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/01.CCM.0000059722.94182.79","article-title":"Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors.","volume":"31","author":"D\u00fcnser","year":"2003","journal-title":"Crit Care Med"},{"issue":"1","key":"joi260122r20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1060028016669163","article-title":"Efficacy and outcomes after vasopressin guideline implementation in septic shock.","volume":"51","author":"Wu","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"3","key":"joi260122r21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1378\/chest.11-2604","article-title":"The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock.","volume":"142","author":"Gordon","year":"2012","journal-title":"Chest"},{"issue":"12","key":"joi260122r22","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1513\/AnnalsATS.202102-196OC","article-title":"Practice patterns in the initiation of secondary vasopressors and adjunctive corticosteroids during septic shock in the United States.","volume":"18","author":"Bosch","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"joi260122r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.chstcc.2025.100178","article-title":"Protocol and statistical analysis plan for the Vasopressin for Septic Shock Pragmatic (VASSPR) cluster-crossover randomized trial.","volume":"3","author":"Peltan","year":"2025","journal-title":"CHEST Crit Care"},{"key":"joi260122r24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials.","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"key":"joi260122r25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080472","article-title":"Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration.","volume":"388","author":"McKenzie","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"joi260122r26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/CCM.0000000000006176","article-title":"Position paper on the reporting of norepinephrine formulations in critical care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force.","volume":"52","author":"Wieruszewski","year":"2024","journal-title":"Crit Care Med"},{"issue":"1","key":"joi260122r27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1164\/rccm.201212-2199OC","article-title":"Multicenter implementation of a severe sepsis and septic shock treatment bundle.","volume":"188","author":"Miller","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"joi260122r29","first-page":"1","article-title":"Building a comprehensive clinical information system from components: the approach at Intermountain Health Care.","volume":"42","author":"Clayton","year":"2003","journal-title":"Methods Inf Med"},{"issue":"12","key":"joi260122r30","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/cid\/ciad101","article-title":"Concordance between initial presumptive and final adjudicated diagnoses of infection among patients meeting Sepsis-3 criteria in the emergency department.","volume":"76","author":"Hooper","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"joi260122r31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"issue":"6","key":"joi260122r32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bjc.1976.220","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient, I: introduction and design.","volume":"34","author":"Peto","year":"1976","journal-title":"Br J Cancer"},{"issue":"526","key":"joi260122r33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","article-title":"Repeated assessment of results in clinical trials of cancer treatment.","volume":"44","author":"Haybittle","year":"1971","journal-title":"Br J Radiol"},{"issue":"9471","key":"joi260122r34","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(05)66516-6","article-title":"Multiplicity in randomised trials II: subgroup and interim analyses.","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"joi260122r35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"issue":"5","key":"joi260122r36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233495","article-title":"Comparative evaluation of the clinical laboratory-based Intermountain risk score with the Charlson and Elixhauser comorbidity indices for mortality prediction.","volume":"15","author":"Snow","year":"2020","journal-title":"PLoS One"},{"key":"joi260122r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2026.155667","article-title":"Effects of a policy intended to reduce vasopressin use in intensive care unit patients with shock.","volume":"95","author":"McCarthy","year":"2026","journal-title":"J Crit Care"},{"issue":"4","key":"joi260122r38","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/CCM.0000000000005305","article-title":"Association between vasopressin rebranding and utilization in patients with septic shock.","volume":"50","author":"Sacha","year":"2022","journal-title":"Crit Care Med"},{"issue":"1","key":"joi260122r39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00134-024-07735-7","article-title":"Management of adult sepsis in resource-limited settings: global expert consensus statements using a Delphi method.","volume":"51","author":"Thwaites","year":"2025","journal-title":"Intensive Care Med"},{"issue":"5","key":"joi260122r41","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.chest.2023.07.009","article-title":"Optimizing vasopressin use and initiation timing in septic shock: a narrative review.","volume":"164","author":"Sacha","year":"2023","journal-title":"Chest"},{"issue":"1","key":"joi260122r42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13054-025-05401-y","article-title":"Effect of early adjunctive vasopressin initiation for septic shock patients: a target trial emulation.","volume":"29","author":"White","year":"2025","journal-title":"Crit Care"},{"issue":"9","key":"joi260122r43","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000001284","article-title":"Vasopressin initiation timing and in-hospital mortality in septic shock: an observational study of large public databases.","volume":"7","author":"Sacha","year":"2025","journal-title":"Crit Care Explor"},{"key":"joi260122r44","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-026-08575-3","article-title":"Ultra-early versus early adjunctive vasopressin initiation after norepinephrine escalation in septic shock: a target trial emulation.","author":"Nakashima","journal-title":"Intensive Care Med"},{"key":"joi260122r45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2516225","article-title":"Vasopressors or fluids in early septic shock.","author":"Peake","journal-title":"N Engl J Med"},{"issue":"6","key":"joi260122r46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1056\/NEJMoa2212663","article-title":"Early restrictive or liberal fluid management for sepsis-induced hypotension.","volume":"388","author":"Shapiro","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"joi260122r47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13054-022-04001-4","article-title":"When to start vasopressin in septic shock: the strategy we propose.","volume":"26","author":"Guerci","year":"2022","journal-title":"Crit Care"},{"issue":"22","key":"joi260122r48","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1001\/jama.2025.20402","article-title":"Personalized hemodynamic resuscitation targeting capillary refill time in early septic shock: the ANDROMEDA-SHOCK-2 randomized clinical trial.","volume":"334","author":"Hernandez","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"joi260122r49","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/CCM.0000000000005317","article-title":"Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock.","volume":"50","author":"Sacha","year":"2022","journal-title":"Crit Care Med"},{"issue":"11","key":"joi260122r50","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S2213-2600(23)00237-0","article-title":"Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials.","volume":"11","author":"Sinha","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"20","key":"joi260122r51","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis.","volume":"321","author":"Seymour","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"joi260122r52","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/17407745231186094","article-title":"Informative cluster size in cluster-randomised trials: a case study from the TRIGGER trial.","volume":"20","author":"Kahan","year":"2023","journal-title":"Clin Trials"},{"key":"joi260122r40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-03143-5_7","volume-title":"Sepsis Management in Resource-Limited Settings","author":"Misango","year":"2019"},{"key":"joi260122r28","unstructured":"Intermountain Health. Care process model: recognition and management of adult severe sepsis and septic shock. Accessed January 25, 2024. https:\/\/intermountainhealthcare.org\/ckr-ext\/Dcmnt?ncid=529626993"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2855462\/jama_peltan_2026_oi_260122_1791579719.68213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:30:25Z","timestamp":1791984625000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2855462"}},"subtitle":["The VASSPR Cluster Crossover Randomized Strategy Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.21333","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,14]]}}}